[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Merit Medical Systems, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,70,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100578115","wrap-north-america-100578115",false,"NCT06807099","WRAP North America","Prospective, Multicenter, Observational Study to Evaluate the Merit WRAPSODY® Cell Impermeable Endoprosthesis for Treatment of Stenosis or Occlusion Within the Dialysis Outflow Circuit (WRAP North America)","Inclusion Criteria:\n\n1. Subject provides written informed consent for study participation.\n2. Subject is male or female, with an age ≥ 18 years at date of enrollment.\n3. Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 36 months.\n4. Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon.\n5. The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session.\n6. Subject has stenosis or occlusion within the dialysis outflow circuit and is treated with WRAPSODY CIE in accordance with device instructions for use.\n\nExclusion Criteria:\n\n1. Subject has a planned surgical revision of access site.\n2. Subject has a known or suspected infection of the hemodialysis access site, systemic infection and\u002For septicemia.\n3. Subject has an uncorrectable coagulation disorder.\n4. Known hypersensitivity to nickel or titanium.\n5. Subject's hemodialysis access is anticipated to be abandoned within 6 months.\n6. Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure.\n7. Full expansion of a PTA balloon cannot be achieved during predilatation.\n8. Device would be placed in the Superior Vena Cava\n9. Any inflow or outflow lesion that could jeopardize patency access long-term beyond the target treatment area.","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to investigate the safety and efficacy of the WRAPSODY CIE in a real-world North American population. Participants treated with the WRAPSODY CIE device in accordance with the device instructions for use will be followed in accordance with standard of care up to 3-years post-procedure.",[24,25],"Venous Stenosis","Venous Occlusion",[27,28,29,30],"Arteriovenous Fistula (AVF)","Arteriovenous Graft (AVG)","AV fistula","AV graft","RECRUITING","2026-06-16",{"date":34,"type":35},"2026-06-17","ACTUAL",{"date":37,"type":35},"2025-07-31",{"date":39,"type":20},"2030-07",{"name":41,"class":42},"Merit Medical Systems, Inc.","INDUSTRY",16,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100548582","preserve-hd-observational-study-of-the-merit-hero-graft-and-super-hero-in-patients-on-hemodialysis-100548582","NCT06422871","PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis","PReSeRVE-HD: PRospective, Multicenter, Observational Study of the Merit HeRO® Graft and Super HeRO® EValuated in End-Stage Renal Disease Patients on HemoDialysis","PReSeRVE-HD","Key Inclusion Criteria:\n\n* Subject provides written informed consent\n* Subject is ≥ 18 years\n* Subject is end-stage renal disease patient on hemodialysis.\n* Subject is treated with HeRO Graft or Super HeRO System in accordance with device instructions for use (IFU)\n\nKey Exclusion Criteria:\n\n* Subject has a previously placed HeRO or Super HeRO device that is undergoing revision or replacement\n* Subject has a topical or subcutaneous infection associated with the implantation site\n* Subject has known or suspected systemic infection, bacteremia or septicemia",{"count":53,"type":20},100,"2 Years","The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of their regular medical care for maintaining long-term dialysis access when all other dialysis access options have failed. If participants in the study are not seen for a standard of care clinic visit during the 4 visit timepoints over 2 years, the participant will be followed by phone to check their current health and dialysis status.",[57,58],"End Stage Renal Disease","Hemodialysis Access Failure",[60],"HeRO","2026-05-28",{"date":63,"type":35},"2026-06-01",{"date":65,"type":35},"2025-07-28",{"date":67,"type":20},"2028-12-28",{"name":41,"class":42},7,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":5},"100527892","bearing-nspva-embolization-for-uterine-artery-embolization-better-uae-100527892","NCT06153667","Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)","Prospective, Multi-Center Study Using Bearing nsPVA Embolization Particles for the Treatment of uTErine fibRoids With Uterine Artery Embolization","BETTER-UAE","Inclusion Criteria:\n\n* Adult women ≥ 18 years old at the time of enrollment.\n* Subject has symptomatic uterine fibroid(s), suitable to embolization.\n* Subject provides written informed consent.\n\nExclusion Criteria:\n\n* Subject is pregnant.\n* Subject has suspected pelvic inflammatory disease or any other pelvic infection.\n* Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).","FEMALE",{"count":53,"type":20},"This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.",[82],"Uterine Fibroid",{"date":84,"type":35},"2026-05-29",{"date":86,"type":35},"2024-08-22",{"date":88,"type":20},"2026-12",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100443162","us-post-market-surveillance-study-of-the-surfacer-system-100443162","NCT05050799","US Post-Market Surveillance Study of the Surfacer System","US Post-Market Surveillance Study of the Surfacer* Inside-Out* Access Catheter System (Surfacer System)","Inclusion Criteria:\n\n1. Subjects have been referred for placement of central venous access, i.e., placement of catheter, nutritional line, etc.\n2. Subjects with upper body venous occlusions or other conditions that preclude central venous access by conventional methods\n3. Subjects are willing and able to give written informed consent\n\nExclusion Criteria:\n\n1. Occlusion of the right femoral vein, right iliac vein or inferior vena cava\n2. Acute thrombus within any vessel to be crossed by Surfacer System (SVC, jugular, IVC, brachiocephalic and subclavian)\n3. Occlusion within the arterial system\n4. Occlusion within the coronary or cerebral vasculature",{"count":98,"type":20},30,"Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.",[101],"Venous Disease",{"date":63,"type":35},{"date":104,"type":35},"2022-02-08",{"date":106,"type":20},"2026-12-15",{"name":41,"class":42},9,""]